Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVTN 112: HIV-1 pDNA and rVSV Prime-Boost Vaccine Trial
NCT02654080Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2016
- Primary completion
- Aug 2017
- Modality
- Gene Editing, Viral Vector Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HIV-1 nef/tat/vif, env pDNA and rVSV HIV envC in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of local injection/EP site and systemic reactogenicity signs and symptoms at Month 15, Severity of local injection/EP site and systemic reactogenicity signs and symptoms at Month 15 and 4 more. Started Mar 2016; status: completed.
02
Drugs
HIV-1 nef/tat/vif, env pDNArVSV HIV envC
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02654080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654080.